Latest News and Press Releases
Want to stay updated on the latest news?
-
Dublin, Oct. 13, 2022 (GLOBE NEWSWIRE) -- The "Asparaginase Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Application, End-Use Industry, and Geography" report has been added...
-
Dublin, Sept. 10, 2020 (GLOBE NEWSWIRE) -- The "Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's...
-
LYON, France et CAMBRIDGE, Mass., 20 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), société biopharmaceutique de stade clinique qui développe des thérapies...
-
LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies...
-
Conférence téléphonique et webcast : mardi 11 septembre à 14h30 Confirmation du virage stratégique entrepris vers le développement d’eryaspase dans les tumeurs solidesLancement de l’étude de Phase...
-
Conference call and webcast scheduled for Tuesday, September 11that 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmedPhase 3 trial for eryaspase in second...
-
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...
-
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
-
LYON, France, May 14, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...
-
LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of...